The adenosine deaminase-severe combined immunodeficiency market size has grown strongly in recent years. It will grow from $5.57 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of severe combined immunodeficiency, an increasing incidence of primary immunodeficiencies (PID), a growing burden of immunodeficiency disorders, higher healthcare investments, and greater awareness of immunodeficiencies.
The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $7.7 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be driven by the rising prevalence of genetic disorders, increased use of bone marrow transplantation, growing demand for non-conditioned stem cell transplantation, a higher prevalence of ADA deficiency, and a rising number of adenosine deaminase deficiency (PDA) cases. Key trends in this period include technological advancements, the adoption of gene therapy, government initiatives, advancements in genetic testing, and progress in biotechnology.
The increasing prevalence of genetic disorders is expected to drive the growth of the adenosine deaminase-severe combined immunodeficiency (ADA-SCID) market. Genetic disorders result from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Factors such as advancements in diagnostic technologies, greater awareness, higher parental age, environmental influences, and population growth contribute to the rising prevalence of genetic conditions. In particular, the increasing occurrence of genetic disorders, including ADA-SCID, is fueling the demand for advanced diagnostic techniques and targeted treatments. For example, in December 2022, a report published by the Department of Health & Social Care (DHSC), a UK-based government department, revealed that as of October 2022, approximately 33,000 whole genome equivalents had been sequenced, with an average diagnostic yield of 32%, rising to 61% in specific conditions. Consequently, the growing prevalence of genetic disorders is propelling the expansion of the ADA-SCID market.
Leading companies in the ADA-SCID market are prioritizing the development of innovative treatments, such as gene therapy, to improve patient outcomes, enhance survival rates, and address the underlying genetic causes of the disorder using advanced medical technologies. Gene therapy for ADA-SCID aims to correct the genetic defect by introducing a functional copy of the ADA gene, potentially offering a long-term cure for this rare and life-threatening immune condition. For instance, in May 2022, Danaher Corporation, a US-based life sciences and diagnostics company, joined the Bespoke Gene Therapy Consortium (BGTC) as part of the Accelerating Medicines Partnership (AMP) program. This initiative, in collaboration with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical companies, and non-profit organizations, seeks to advance customized gene therapies for rare diseases and streamline their development. This collaboration is particularly important as it addresses the challenges of traditional drug development for rare diseases, which often receive limited commercial interest due to their low prevalence.
In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc. for an undisclosed amount. This acquisition enhances Kyowa Kirin’s focus on developing innovative treatments for rare and complex diseases by leveraging Orchard Therapeutics’ expertise in gene therapy. Orchard Therapeutics plc, a UK-based company, specializes in creating gene therapies for rare genetic disorders.
Major players in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc., Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, and QED Bioscience Inc.
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in adenosine deaminase-severe combined immunodeficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the adenosine deaminase-severe combined immunodeficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by a deficiency of the enzyme adenosine deaminase, resulting in the toxic accumulation of metabolites that hinder immune cell development. Understanding ADA-SCID is crucial for early diagnosis and management to prevent life-threatening infections and complications.
The primary treatment options for ADA-SCID include enzyme replacement therapy (ERT), gene therapy, stem cell transplantation, and supportive care. ERT involves administering synthetic or recombinant enzymes to compensate for the deficient or absent enzyme in individuals with genetic disorders. These therapies are delivered through various routes, including intravenous, subcutaneous, and oral administration. Designed for both pediatric and adult patients, they are distributed through hospital, retail, and online pharmacies. Key end-users include hospitals, specialty clinics, research institutes, and other healthcare facilities.
The adenosine deaminase-severe combined immunodeficiency market research report is one of a series of new reports that provides adenosine deaminase-severe combined immunodeficiency market statistics, including the adenosine deaminase-severe combined immunodeficiency industry global market size, regional shares, competitors with the adenosine deaminase-severe combined immunodeficiency market share, detailed adenosine deaminase-severe combined immunodeficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the adenosine deaminase-severe combined immunodeficiency industry. This adenosine deaminase-severe combined immunodeficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The adenosine deaminase-severe combined immunodeficiency market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, therapy services, and consultation & genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine deaminase-severe combined immunodeficiency market also includes sales of diagnostic tools, supportive therapies, and genetic testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $7.7 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be driven by the rising prevalence of genetic disorders, increased use of bone marrow transplantation, growing demand for non-conditioned stem cell transplantation, a higher prevalence of ADA deficiency, and a rising number of adenosine deaminase deficiency (PDA) cases. Key trends in this period include technological advancements, the adoption of gene therapy, government initiatives, advancements in genetic testing, and progress in biotechnology.
The increasing prevalence of genetic disorders is expected to drive the growth of the adenosine deaminase-severe combined immunodeficiency (ADA-SCID) market. Genetic disorders result from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Factors such as advancements in diagnostic technologies, greater awareness, higher parental age, environmental influences, and population growth contribute to the rising prevalence of genetic conditions. In particular, the increasing occurrence of genetic disorders, including ADA-SCID, is fueling the demand for advanced diagnostic techniques and targeted treatments. For example, in December 2022, a report published by the Department of Health & Social Care (DHSC), a UK-based government department, revealed that as of October 2022, approximately 33,000 whole genome equivalents had been sequenced, with an average diagnostic yield of 32%, rising to 61% in specific conditions. Consequently, the growing prevalence of genetic disorders is propelling the expansion of the ADA-SCID market.
Leading companies in the ADA-SCID market are prioritizing the development of innovative treatments, such as gene therapy, to improve patient outcomes, enhance survival rates, and address the underlying genetic causes of the disorder using advanced medical technologies. Gene therapy for ADA-SCID aims to correct the genetic defect by introducing a functional copy of the ADA gene, potentially offering a long-term cure for this rare and life-threatening immune condition. For instance, in May 2022, Danaher Corporation, a US-based life sciences and diagnostics company, joined the Bespoke Gene Therapy Consortium (BGTC) as part of the Accelerating Medicines Partnership (AMP) program. This initiative, in collaboration with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical companies, and non-profit organizations, seeks to advance customized gene therapies for rare diseases and streamline their development. This collaboration is particularly important as it addresses the challenges of traditional drug development for rare diseases, which often receive limited commercial interest due to their low prevalence.
In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc. for an undisclosed amount. This acquisition enhances Kyowa Kirin’s focus on developing innovative treatments for rare and complex diseases by leveraging Orchard Therapeutics’ expertise in gene therapy. Orchard Therapeutics plc, a UK-based company, specializes in creating gene therapies for rare genetic disorders.
Major players in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc., Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, and QED Bioscience Inc.
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in adenosine deaminase-severe combined immunodeficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the adenosine deaminase-severe combined immunodeficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by a deficiency of the enzyme adenosine deaminase, resulting in the toxic accumulation of metabolites that hinder immune cell development. Understanding ADA-SCID is crucial for early diagnosis and management to prevent life-threatening infections and complications.
The primary treatment options for ADA-SCID include enzyme replacement therapy (ERT), gene therapy, stem cell transplantation, and supportive care. ERT involves administering synthetic or recombinant enzymes to compensate for the deficient or absent enzyme in individuals with genetic disorders. These therapies are delivered through various routes, including intravenous, subcutaneous, and oral administration. Designed for both pediatric and adult patients, they are distributed through hospital, retail, and online pharmacies. Key end-users include hospitals, specialty clinics, research institutes, and other healthcare facilities.
The adenosine deaminase-severe combined immunodeficiency market research report is one of a series of new reports that provides adenosine deaminase-severe combined immunodeficiency market statistics, including the adenosine deaminase-severe combined immunodeficiency industry global market size, regional shares, competitors with the adenosine deaminase-severe combined immunodeficiency market share, detailed adenosine deaminase-severe combined immunodeficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the adenosine deaminase-severe combined immunodeficiency industry. This adenosine deaminase-severe combined immunodeficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The adenosine deaminase-severe combined immunodeficiency market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, therapy services, and consultation & genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine deaminase-severe combined immunodeficiency market also includes sales of diagnostic tools, supportive therapies, and genetic testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Adenosine Deaminase-Severe Combined Immunodeficiency Market Characteristics3. Adenosine Deaminase-Severe Combined Immunodeficiency Market Trends And Strategies4. Adenosine Deaminase-Severe Combined Immunodeficiency Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Adenosine Deaminase-Severe Combined Immunodeficiency Market34. Recent Developments In The Adenosine Deaminase-Severe Combined Immunodeficiency Market
5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Growth Analysis And Strategic Analysis Framework
6. Adenosine Deaminase-Severe Combined Immunodeficiency Market Segmentation
7. Adenosine Deaminase-Severe Combined Immunodeficiency Market Regional And Country Analysis
8. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market
9. China Adenosine Deaminase-Severe Combined Immunodeficiency Market
10. India Adenosine Deaminase-Severe Combined Immunodeficiency Market
11. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market
12. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market
13. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market
14. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market
15. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market
16. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market
17. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market
18. France Adenosine Deaminase-Severe Combined Immunodeficiency Market
19. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market
20. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market
21. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market
22. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market
23. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market
24. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market
25. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market
26. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market
27. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market
28. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market
29. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market
30. Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape And Company Profiles
31. Adenosine Deaminase-Severe Combined Immunodeficiency Market Other Major And Innovative Companies
35. Adenosine Deaminase-Severe Combined Immunodeficiency Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Adenosine Deaminase-Severe Combined Immunodeficiency Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on adenosine deaminase-severe combined immunodeficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for adenosine deaminase-severe combined immunodeficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adenosine deaminase-severe combined immunodeficiency market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Enzyme Replacement Therapy (ERT); Gene Therapy; Stem Cell Transplantation; Supportive Care Treatments2) By Route of Administration: Intravenous; Subcutaneous; Oral
3) By Age Group: Pediatric (Infants and Children); Adults
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Others End-Users
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement; Pegylated Erythropoietin (PEG-EPO)2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy; Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant; Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy; Immune System Support; Nutritional Support
Key Companies Profiled: Novartis AG; GlaxoSmithKline plc (GSK); Astellas Pharma; Orient EuroPharma; Charles River Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Adenosine Deaminase-Severe Combined Immunodeficiency market report include:- Novartis AG
- GlaxoSmithKline plc (GSK)
- Astellas Pharma
- Orient EuroPharma
- Charles River Laboratories
- Chiesi Farmaceutici S.p.A.
- Spark Therapeutics
- Rocket Pharmaceuticals
- Bluebird Bio
- Ospedale San Raffaele (OSR)
- Oxford Biomedica PLC
- Teijin Pharma
- Leadiant Biosciences
- Orchard Therapeutics PLC
- Fondazione Telethon
- Mustang Bio Inc
- Sigma-Tau Pharmaceuticals
- Shenzhen Geno-Immune Medical Institute
- ENZON Pharmaceuticals
- QED Bioscience Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | January 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 5.95 Billion |
Forecasted Market Value ( USD | $ 7.7 Billion |
Compound Annual Growth Rate | 6.6% |
Regions Covered | Global |
No. of Companies Mentioned | 20 |